amyloid-β (aβ) self-assembly into cross-β amyloidfibrils is implicated in a causative role in alzheimer’s disease pathology.uncertainties persist regarding the mechanisms of amyloid self assembly and the role of metastable prefibrillar aggregates. aβ fibrilsfeature a sheet-turn-sheet motif in the constituent β-strands; as such, turn nucleation has been proposed as a rate-limiting step in the se...

background: alzheimer’s disease (ad) is a neurodegenerative disorder with progressive loss of cognitive abilities and memory loss. the aim of this study was to compare neuropathological changes in hippocampus and brain cortex in a rat model of ad. methods: adult male albino wistar rats (weighing 250-300 g) were used for behavioral and histopathological studies. the rats were randomly assigned t...

OBJECTIVES To investigate dynamic changes in human plasma β-amyloid (Aβ) concentrations, evaluate the effects of aging and amyloidosis on these dynamics, and determine their correlation with cerebrospinal fluid (CSF) Aβ concentrations. DESIGN A repeated plasma and CSF sampling study. SETTING The Washington University School of Medicine in St Louis, Missouri. PARTICIPANTS Older adults with...

The 25-35 fragment of the amyloid β (Aβ) peptide is a naturally occurring proteolytic by-product of its larger parent molecule that retains the amyloid characteristics and toxicity of the full length parent molecule. Aggregation of this peptide occurs rapidly in aqueous solutions and thus characterization of its folding process is very difficult. In the present study, early stages of Aβ(25–35) ...

Background: AD is a neurodegenerative disorder in which there is a gathering of beta-amyloid plaques, primarily in the hippocampus, that lead to neuronal death. Exercise training and botanical medications can play a role in the prevention and treatment of neurodegenerative disorders. Objective: The aim of this study was to determine the effects of aerobic training and Salvia officinalis extract...

BACKGROUND The amyloid hypothesis predicts that increased production or decreased clearance of β-amyloid (Aβ) leads to amyloidosis, which ultimately culminates in Alzheimer disease (AD). OBJECTIVE To investigate whether dynamic changes in Aβ levels in the human central nervous system may be altered by aging or by the pathology of AD and thus contribute to the risk of AD. DESIGN Repeated-mea...

A hallmark of Alzheimer’s disease is the accumulation amyloid-β (Aβ) peptide. Donanemab, an antibody that targets a modified form deposited Aβ, being investigated for treatment early disease.

BACKGROUND Amyloid positron emission tomography (PET) has become an important tool to identify amyloid-β (Aβ) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [(18)F]flutemetamol in relation to Aβ pathology at autopsy. METHODS [(18)F]flutemetamol PET was carried out in a cohort of 68 patients included in a [(18)F]flutemetamol a...

Cerebrovascular accumulation of amyloid β-protein (Aβ), a condition known as cerebral amyloid angiopathy (CAA), is a common pathological feature of patients with Alzheimer's disease. Familial Aβ mutations, such as Dutch-E22Q and Iowa-D23N, can cause severe cerebrovascular accumulation of amyloid that serves as a potent driver of vascular cognitive impairment and dementia. The distinctive featur...

Background and objectives: Alzheimer's disease (AD) as a neurodegenerative disorder is the most common form of dementia in the elderly. According to the amyloid hypothesis, accumulation of amyloid beta (Aβ) plaques, which are mostly constituted of Aβ peptide aggregates, triggers pathological cascades that lead to neuronal cell death. Thus, modulation of Aβ toxicity is the hopef...